“…There is a growing body of literature demonstrating that circulating mtDNA levels are elevated in large variety of human diseases, including sepsis ( 29 – 36 , 191 , 192 ), trauma, pulmonary embolism ( 193 ), liver failure ( 53 , 54 ), stroke ( 57 ), and cancer ( 45 – 50 ). Numerous recent clinical studies have suggested that mtDNA circulating level may represent a new biological marker of the severity of tissue injury for critical ill patient admitted with sever sepsis ( 29 – 36 , 191 , 192 ), trauma ( 13 , 31 , 36 , 39 – 42 ), myocardial infarction ( 194 , 195 ), and cardiogenic shock ( 44 ) since a correlation between mtDNA levels, injury severity and outcome has frequently been observed ( 30 , 32 , 36 , 39 , 41 , 192 ). Interestingly, Krychtiuk et al ( 30 ) demonstrated not only that mtDNA levels were associated with mortality in critical ill patients but also that TLR9 expression in patients increase the association between mtDNA and mortality.…”